Alain Couvineau

List of Publications by Year
in descending order

123 papers	4,882 citations	87888 38 h-index	98798 67 g-index
125 all docs	125 docs citations	125 times ranked	5362 citing authors

#	Article	IF	Citations
1	Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia.. Journal of Clinical Investigation, 1998, 102, 34-40.	8.2	292
2	Novel Receptor Partners and Function of Receptor Activity-modifying Proteins. Journal of Biological Chemistry, 2003, 278, 3293-3297.	3.4	283
3	Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. Peptides, 2007, 28, 1631-1639.	2.4	183
4	A Homozygous Inactivating Mutation in the Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Causing Blomstrand Chondrodysplasia. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3373-3376.	3.6	171
5	Recurrent<i>PRKAR1A</i>Mutation in Acrodysostosis with Hormone Resistance. New England Journal of Medicine, 2011, 364, 2218-2226.	27.0	162
6	Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist. Journal of Biological Chemistry, 2000, 275, 24003-24012.	3.4	156
7	Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regulatory Peptides, 2002, 108, 165-173.	1.9	155
8	Human Intestinal VIP Receptor: Cloning and Functional Expression of Two cDNA Encoding Proteins with Different N-Terminal Domains. Biochemical and Biophysical Research Communications, 1994, 200, 769-776.	2.1	146
9	Interaction of Peptide YY with Rat Intestinal Epithelial Plasma Membranes: Binding of the Radioiodinated Peptide. Endocrinology, 1986, 118, 1910-1917.	2.8	144
10	Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP-1, and Other Members of Their New Family of G Protein-Linked Receptors: Structure-Function Relationship with Special Reference to the Human VIP-1 Receptora. Annals of the New York Academy of Sciences, 1996, 805, 94-109.	3.8	120
11	Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides, 2008, 29, 919-932.	2.4	109
12	A Heterotrimeric G i3-protein Controls Autophagic Sequestration in the Human Colon Cancer Cell Line HT-29. Journal of Biological Chemistry, 1995, 270, 13-16.	3.4	106
13	PTHR1 mutations associated with Ollier disease result in receptor loss of function. Human Molecular Genetics, 2008, 17, 2766-2775.	2.9	103
14	Mutagenesis of N-Glycosylation Sites in the Human Vasoactive Intestinal Peptide 1 Receptor. Evidence That Asparagine 58 or 69 Is Crucial for Correct Delivery of the Receptor to Plasma Membraneâ€. Biochemistry, 1996, 35, 1745-1752.	2.5	102
15	Galanin Receptors in a Hamster Pancreatic Î²-Cell Tumor: Identification and Molecular Characterization. Endocrinology, 1987, 121, 284-289.	2.8	96
16	Highly Conserved Aspartate 68, Tryptophane 73 and Glycine 109 in the N-Terminal Extracellular Domain of the Human VIP Receptor Are Essential for Its Ability to Bind VIP. Biochemical and Biophysical Research Communications, 1995, 206, 246-252.	2.1	95
17	VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. British Journal of Pharmacology, 2012, 166, 42-50.	5.4	95
18	Class-B GPCR activation: is ligand helix-capping the key?. Trends in Biochemical Sciences, 2008, 33, 314-319.	7.5	93

#	Article	IF	Citations
19	Molecular and Conformational Determinants of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) for Activation of the PAC1 Receptor. Journal of Medicinal Chemistry, 2009, 52, 3308-3316.	6.4	76
20	Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: Effect of nine partial sequences. Biochemical and Biophysical Research Communications, 1984, 121, 493-498.	2.1	75
21	The Human Vasoactive Intestinal Peptide Receptor: Molecular Identification by Covalent Cross-Linking in Colonic Epithelium*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 50-55.	3.6	72
22	Mutational Analysis of Cysteine Residues within the Extracellular Domains of the Human Vasoactive Intestinal Peptide (VIP) 1 Receptor Identifies Seven Mutants That Are Defective in VIP Binding. Biochemical and Biophysical Research Communications, 1995, 211, 901-908.	2.1	71
23	Regional Expression of Epithelial Dipeptidyl Peptidase IV in the Human Intestines. Biochemical and Biophysical Research Communications, 1994, 203, 1224-1229.	2.1	69
24	Neurotensin Receptor and Its mRNA Are Expressed in Many Human Colon Cancer Cell Lines But Not in Normal Colonic Epithelium: Binding Studies and RT-PCR Experiments. Biochemical and Biophysical Research Communications, 1994, 203, 465-471.	2.1	68
25	Vasoactive Intestinal Peptide (VIP)1 Receptor. Journal of Biological Chemistry, 1996, 271, 12795-12800.	3.4	67
26	Constitutive Activation of the Human Vasoactive Intestinal Peptide 1 Receptor, a Member of the New Class II Family of G Protein-coupled Receptors. Journal of Biological Chemistry, 1998, 273, 4990-4996.	3.4	61
27	Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor. Journal of Biological Chemistry, 2006, 281, 12792-12798.	3.4	58
28	Molecular Analysis of Vasoactive Intestinal Peptide Receptors: A Comparison with Receptors for VIP-Related Peptides. Annals of the New York Academy of Sciences, 1988, 527, 296-313.	3.8	52
29	The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins. Current Drug Targets, 2012, 13, 103-115.	2.1	51
30	Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosa.. Journal of Clinical Investigation, 1993, 91, 2049-2057.	8.2	51
31	Discovery of a functional immunoreceptor tyrosineâ€•based switch motif in a 7â€transmembraneâ€spanning receptor: role in the orexin receptor OX1Râ€driven apoptosis. FASEB Journal, 2009, 23, 4069-4080.	0.5	48
32	Identification of Cytoplasmic Domains of hVPAC1 Receptor Required for Activation of Adenylyl Cyclase. Journal of Biological Chemistry, 2003, 278, 24759-24766.	3.4	45
33	Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced inÂvivo cardiovascular side effects in a Parkinson's disease model. Neuropharmacology, 2016, 108, 440-450.	4.1	44
34	Photoaffinity Labeling Demonstrates Physical Contact between Vasoactive Intestinal Peptide and the N-terminal Ectodomain of the Human VPAC1 Receptor. Journal of Biological Chemistry, 2003, 278, 36531-36536.	3.4	42
35	A Homozygous Inactivating Mutation in the Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Causing Blomstrand Chondrodysplasia. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3373-3376.	3.6	42
36	The Human VPAC1 Receptor. Journal of Biological Chemistry, 2001, 276, 10153-10160.	3.4	41

#	Article	IF	Citations
37	Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Frontiers in Endocrinology, 2019, 10, 709.	3.5	41
38	Aspartate 196 in the First Extracellular Loop of the Human VIP1 Receptor Is Essential for VIP Binding and VIP-Stimulated cAMP Production. Biochemical and Biophysical Research Communications, 1997, 230, 289-292.	2.1	40
39	The Vasoactive Intestinal Peptide (VIP) Î±-Helix Up to C Terminus Interacts with the N-Terminal Ectodomain of the Human VIP/Pituitary Adenylate Cyclase-Activating Peptide 1 Receptor: Photoaffinity, Molecular Modeling, and Dynamics. Molecular Endocrinology, 2008, 22, 147-155.	3.7	39
40	Solubilization and molecular characterization of active galanin receptors from rat brain. Biochemistry, 1992, 31, 2415-2422.	2.5	37
41	Molecular Characteristics and Peptide Specificity of Vasoactive Intestinal Peptide Receptors from Rat Cerebral Cortex. Journal of Neurochemistry, 1986, 47, 1469-1475.	3.9	35
42	Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: Comparison with rat intestinal receptors. Life Sciences, 1985, 36, 991-995.	4.3	33
43	PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: Involvement of the mitochondrial apoptotic pathway. Neurobiology of Disease, 2008, 32, 66-80.	4.4	32
44	Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation. Journal of Neuroinflammation, 2019, 16, 64.	7.2	32
45	The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. European Journal of Cancer, 2014, 50, 2126-2133.	2.8	31
46	Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver. FEBS Journal, 1990, 187, 605-609.	0.2	29
47	VPAC1 receptor binding site: Contribution of photoaffinity labeling approach. Neuropeptides, 2010, 44, 127-132.	2.2	28
48	Functional Characterization of PRKAR1A Mutations Reveals a Unique Molecular Mechanism Causing Acrodysostosis but Multiple Mechanisms Causing Carney Complex. Journal of Biological Chemistry, 2015, 290, 27816-27828.	3.4	28
49	Diffuse Pharmacophoric Domains of Vasoactive Intestinal Peptide (VIP) and Further Insights into the Interaction of VIP with the N-terminal Ectodomain of Human VPAC1 Receptor by Photoaffinity Labeling with [Bpa6]-VIP. Journal of Biological Chemistry, 2004, 279, 38889-38894.	3.4	27
50	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	3.7	26
51	Biological and Structural Analysis of Truncated Analogs of PACAP27. Journal of Molecular Neuroscience, 2008, 36, 260-269.	2.3	25
52	Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB Journal, 2012, 26, 2060-2071.	0.5	25
53	Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3618-3628.	3.8	25
54	Signal Transduction by VIP and PACAP Receptors. Biomedicines, 2022, 10, 406.	3.2	25

#	Article	IF	Citations
55	The CIP receptor on pancreatic beta cell tumor: Molecular identification by covalent cross-linking. Biochemical and Biophysical Research Communications, 1984, 122, 283-288.	2.1	24
56	Phorbol ester induces loss of VIP stimulation of adenylate cyclase and VIP-binding sites in HT29 cells. FEBS Letters, 1987, 211, 151-154.	2.8	24
57	GÎ±i RNA Antisense Expression Demonstrates the Exclusive Coupling of Peptide YY Receptors to Gi2 Proteins in Renal Proximal Tubule Cells. Journal of Biological Chemistry, 1996, 271, 574-580.	3.4	24
58	The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Frontiers in Endocrinology, 2018, 9, 573.	3.5	24
59	Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. European Journal of Pharmacology, 1996, 302, 207-214.	3.5	23
60	Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. Regulatory Peptides, 2004, 123, 181-185.	1.9	23
61	Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP. Biochimie, 2011, 93, 669-677.	2.6	23
62	Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS ONE, 2017, 12, e0169908.	2.5	23
63	Gastric inhibitory polypeptide receptor in hamster pancreatic beta cells. Direct cross-linking, solubilization and characterization as a glycoprotein. FEBS Journal, 1986, 159, 353-358.	0.2	22
64	Serine 447 in the Carboxyl Tail of Human VPAC1 Receptor Is Crucial for Agonist-Induced Desensitization but Not Internalization of the Receptor. Molecular Pharmacology, 2003, 64, 1565-1574.	2.3	21
65	Glycosylation of VIP receptors: A molecular basis for receptor heterogeneity. Peptides, 1993, 14, 483-489.	2.4	20
66	Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides, 2007, 28, 1727-1737.	2.4	20
67	4 Receptors for gut regulatory peptides. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 77-110.	1.0	19
68	The Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase Activating Peptide Receptor 1 (VPAC1): Constitutive Activation by Mutations at Threonine 343. Biochemical and Biophysical Research Communications, 1999, 254, 15-20.	2.1	19
69	The VPAC1 receptor: structure and function of a class B GPCR prototype. Frontiers in Endocrinology, 2012, 3, 139.	3.5	19
70	Crucial role of the orexinâ€B Câ€terminus in the induction of OX₁ receptorâ€mediated apoptosis: analysis by alanine scanning, molecular modelling and siteâ€directed mutagenesis. British Journal of Pharmacology, 2015, 172, 5211-5223.	5.4	19
71	Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons. Neuroscience, 2015, 308, 144-156.	2.3	19
72	Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47phox phosphorylation pathway in monocytes. Mucosal Immunology, 2017, 10, 332-340.	6.0	19

#	Article	IF	Citations
73	<i>In vitro</i>, <i>in vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget, 2018, 9, 6952-6967.	1.8	19
74	Solubilization and hydrodynamic characterization of guanine nucleotide-sensitive vasoactive intestinal peptide-receptor complexes from rat intestine. Biochemistry, 1989, 28, 1667-1672.	2.5	18
75	The N-Terminal Parts of VIP and Antagonist PG97â€“269 Physically Interact with Different Regions of the Human VPAC1 Receptor. Journal of Molecular Neuroscience, 2008, 36, 245-248.	2.3	18
76	Obesity-induced pancreatopathy in rats is reversible after bariatric surgery. Scientific Reports, 2018, 8, 16295.	3.3	18
77	Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium. Life Sciences, 1989, 45, 829-833.	4.3	17
78	Receptors for Peptides of the VIP/PACAP and PYY/NPY/PP Families. , 1999, , 125-157.		14
79	Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World Journal of Gastroenterology, 2021, 27, 7582-7596.	3.3	14
80	Solubilization of active and stable receptors for vasoactive intestinal peptide from rat liver. Regulatory Peptides, 1989, 25, 37-50.	1.9	13
81	Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays. FASEB Journal, 2010, 24, 4585-4598.	0.5	12
82	Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules, 2021, 26, 4849.	3.8	12
83	Tryptophan 67 in the Human VPAC1 Receptor: Crucial Role for VIP Binding. Biochemical and Biophysical Research Communications, 2000, 276, 654-659.	2.1	11
84	Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 631-638.	1.1	11
85	G proteins in rat liver proliferation during cholestasis. Hepatology, 1994, 20, 1041-1047.	7.3	10
86	Human VPAC1 Receptor Selectivity Filter. Journal of Biological Chemistry, 2002, 277, 37016-37022.	3.4	10
87	Construction of Chimeras between Human VIP1 and Secretin Receptors: Identification of Receptor Domains Involved in Selectivity towards VIP, Secretin, and PACAP. Annals of the New York Academy of Sciences, 1998, 865, 386-389.	3.8	9
88	Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient. Pediatric Research, 2019, 85, 384-389.	2.3	8
89	Synthesis of a Hydrophilic Affinity Matrix for the Purification of the Vasoactive Intestinal Peptide Receptor. Analytical Biochemistry, 1993, 211, 305-310.	2.4	7
90	The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20. Biochemical Journal, 2000, 347, 623-632.	3.7	7

#	Article	IF	Citations
91	The Human VPAC1 Receptor: Identification of the N-terminal Ectodomain as a Major VIP-Binding Site by Photoaffinity Labeling and 3D Modeling. Annals of the New York Academy of Sciences, 2006, 1070, 205-209.	3.8	7
92	The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Frontiers in Oncology, 0, 12, .	2.8	7
93	VIP receptors from porcine liver: High yield solubilization in a GTP-insensitive form. Life Sciences, 1991, 48, 135-141.	4.3	6
94	Role of Cysteine Residues in the N-Terminal Extracellular Domain of the Human VIP 1 Receptor for Ligand Binding A Site-directed Mutagenesis Studya. Annals of the New York Academy of Sciences, 1996, 805, 585-589.	3.8	6
95	Site-Directed Mutagenesis of Human VIP1 versus VIP2 Receptors. Annals of the New York Academy of Sciences, 1998, 865, 378-381.	3.8	5
96	Cloning and Functional Characterization of the Human VIP1/PACAP Receptor Promoter. Annals of the New York Academy of Sciences, 1998, 865, 59-63.	3.8	4
97	Production and Purification of Large Quantities of the Functional N-Terminal Ectodomain of Human VPAC1 Receptor. Journal of Molecular Neuroscience, 2008, 36, 249-253.	2.3	4
98	Intestinal cell targeting of a stable recombinant Cuâ€"Zn SOD from Cucumis melo fused to a gliadin peptide. Journal of Biotechnology, 2012, 159, 99-107.	3.8	4
99	Strategies for Studying the Ligand Binding Site of GPCRs. Methods in Enzymology, 2013, 520, 219-237.	1.0	4
100	Constitutive Activation of the Human VIP1 Receptor. Annals of the New York Academy of Sciences, 1998, 865, 382-385.	3.8	3
101	The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20. Biochemical Journal, 2000, 347, 623.	3.7	3
102	Gut Peptide Receptors and Signal Transduction in Intestinal Epithelium: State of the Art. Frontiers of Gastrointestinal Research, 0, , 21-33.	0.1	3
103	Localization and Processing of Glycosylphosphatidylinositol-Anchored Cathepsin D. Biochemical and Biophysical Research Communications, 1995, 211, 935-942.	2.1	2
104	Editorial: GPCR in Inflammatory and Cancer Diseases. Frontiers in Endocrinology, 2020, 11, 588157.	3.5	2
105	Common VIP / PACAP receptor in human small intestinal epithelium. Regulatory Peptides, 1992, 40, 242.	1.9	1
106	Mutagenesis of N-Glycosylation Sites in the Human VIP 1 Receptora. Annals of the New York Academy of Sciences, 1996, 805, 558-562.	3.8	1
107	Establishment of a CHO Cell Clone Stably Expressing the Recombinant Human VIP-1 Receptora. Annals of the New York Academy of Sciences, 2006, 805, 570-573.	3.8	1
108	Spatial Approximation between the C-Terminus of VIP and the N-Terminal Ectodomain of the VPAC1 Receptor. Annals of the New York Academy of Sciences, 2006, 1070, 180-184.	3.8	1

#	Article	IF	Citations
109	Expression and GTP Sensitivity of Peptide Histidine Isoleucine High-Affinity-Binding Sites in Rat. Annals of the New York Academy of Sciences, 2006, 1070, 215-219.	3.8	1
110	Characterization of the New Photoaffinity Probe (Bz2-K24)-VIP. Annals of the New York Academy of Sciences, 2006, 1070, 575-580.	3.8	1
111	Tu1498 The Hypothalamic Neuropeptide, Orexin, Prevents Chronic Pancreatitis in Cerulein Mice Model. Gastroenterology, 2016, 150, S917.	1.3	1
112	Solubilization of active VIP-receptor from porcine liver in a GTP-insensitive, G protein-free form. Regulatory Peptides, 1989, 26, 149.	1.9	0
113	Interplay between VIP and PYY/NPY receptors during enterocytic differentiation along the crypt-villus axis in rat small intestine. Regulatory Peptides, 1989, 26, 183.	1.9	0
114	Constitutive activation of the human VIP1/PACAP receptor, a member of the new class II family of G protein-coupled receptors. Gastroenterology, 1998, 114, A1144.	1.3	0
115	Desensitization and internalization of human type 1 vasoactive intestinal peptide receptor(VPAC1)expressed in CHO cells. A mutagenesis study. Gastroenterology, 2003, 124, A466.	1.3	0
116	Tu1834 Orexins Exert a PRO-Apoptotic Effect on Digestive Human Neuroendocrine Tumors (NET) in an Ex-Vivo Culture Model of Tissue Slices. Gastroenterology, 2012, 142, S-857.	1.3	0
117	Sa2023 Importance of the Orexin-B C-Terminal End in the Cellular Apoptosis Induction Mediated by Ox1 Receptor. Gastroenterology, 2013, 144, S-361-S-362.	1.3	0
118	Sa2022 Orexins and Their Gpcr Receptors Ox1r: Antitumoral Effects in Pancreatic Adenocarcinomas. Gastroenterology, 2013, 144, S-361.	1.3	0
119	Mo1684 Anti-Inflammatory Properties of the Neuropeptide Orexins in Ulcerative Colitis: A New Promising Therapeutical Molecule. Gastroenterology, 2015, 148, S-685.	1.3	0
120	Abstract 1215: Orexin and their 7-membrane spanning receptors OX1R: a new colon cancer therapeutic target. , 2012, , .		0
121	Abstract 4214: Antitumoral effects of orexins and their receptors OX1R in pancreatic ductal adenocarcinomas (PDAC). , 2014, , .		0
122	Abstract 5299: The C-terminus of orexin plays a crucial role in the cellular apoptosis induction mediated by OX1 receptor. , 2014, , .		0
123	Abstract 4581: Combination treatment of orexin-A and NAB-paclitaxel in pancreas cancer:in vitroandin vivostudies. , 2016, , .		0